Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
This study has been completed.
Study NCT00141492   Information provided by Solvay Pharmaceuticals
First Received: August 30, 2005   Last Updated: January 29, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes
Hypogonadism
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Gonadal Disorders
Metabolic Diseases
Interventions listed in this trial
Androgel (testosterone gel)
Additional drug interventions recognized in this trial
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
More general drug interventions related to this trial
Anabolic Agents
Androgens
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Solvay Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services